Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Creditors Defer Debts for Nichi-Iko until Turnaround Plan Is Approved
Creditors of Nichi-Iko Pharmaceutical on May 26 agreed to allow the embattled generic maker to defer its debt repayments under an out-of-court turnaround procedure filed earlier this month. The grace period was set until lenders approve the company’s restructuring plan.…
To read the full story
Related Article
- Shingo Iwamoto Sworn in as New Chief of Nichi-Iko; Tamura Bows Out
March 9, 2023
- Nichi-Iko to Discontinue 221 Additional Products, Generic Peers Looking into Impact
March 2, 2023
- Nichi-Iko Exits North American Market, Biosimilar Biz with Sagent Sell-Off
March 1, 2023
- Shareholders OK Nichi-Iko’s Delisting, Turnaround under New Management; President to Exit March 8
February 20, 2023
- Ex-Sandoz Japan Chief Tapped to Spearhead Nichi-Iko Turnaround
January 18, 2023
- Creditors Approve Nichi-Iko’s Turnaround Scheme, Grants Debt Waiver of 98.5 Billion Yen
January 5, 2023
- Mediator Sees Potential for Turnaround in Nichi-Iko’s Restructuring Plan
November 28, 2022
- Nichi-Iko Asks for Debt Waiver from Creditors in Turnaround Plan
November 17, 2022
- Nichi-Iko to Be Delisted, Seeks Turnaround under Medipal-JWP Joint Firm; President to Bow Out
November 15, 2022
- Nichi-Iko Logs 35.6 Billion Yen in Excess Debt in April-September
November 15, 2022
- Nichi-Iko Slides into Excess Debt as Hefty Loss Booked by US Unit
November 9, 2022
- Nichi-Iko Seeks Debt Workout amid US Pipeline Delays and Quality Woes, but President to Stay
May 16, 2022
- Nichi-Iko Files for Debt Reorganization, Incurs Loss of Over 100 Billion Yen
May 13, 2022
BUSINESS
- FRONTEO to Back Biotech Startups with AI and Capital as Third Biz Leg
February 13, 2026
- Biomedix Takes Over Originator Data as Generics Face Supply, Information Challenge
February 13, 2026
- Datroway Filed for 1st-Line TNBC in Japan: Daiichi Sankyo
February 13, 2026
- Nxera Gets US$1.8 Million Early-Stage Milestone from Centessa
February 13, 2026
- Nxera Licenses GPCR Program to European VC-Backed Startup
February 13, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…